KV10.1 | EAG1 | Eag Related Potassium Channel Member 1
Shaker (KV1.1–KV1.8), Shab (KV2.1-KV2.2), Shaw (KV3.1–KV3.4), Shal (KV4.1–KV4.3), KQT like (KV7.1–KV7.5), Eag related (KV10.1-KV10.2), Erg related (KV11.1–KV11.3), Elk related (KV12.1)
Contains six transmembrane domains (S1–S6), four single subunits form a pore, homotetramers and heterotetramers are possible.
KV10.1 Background Information
KV10.1, also known as human ether à-go-go1 protein or EAG1, is the pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel. Upon a depolarization, a slowly activating noninactivating outward current is elicited. Upon repolarization a small tail current occurs. EAG1 is expressed almost exclusively in brain tissue and is involved in cell excitability, memory processes, and cell proliferation. Their expression in over 70% of human tumours makes them an attractive diagnostic and therapeutic target treatment of prostate cancer: The Eag1 K+ channel is especially thought to be involved in the pathophysiological processes of prostate cancer, and is expected to be a valuable target for the diagnosis and treatment of prostate cancer.
Brain (cortex, hippocampus, caudate, putamen, amygdala and weakly in substantia nigra, retina), kidney, lung, pancreas, bone marrow mesenchymal stem cells, heart
Cell proliferation, cell excitability, transformation of epithelial cells, mediates IKNI current in myoblasts
Cancer, Temple-Baraitser Syndrome, Zimmermann-Laband Syndrome 1, myasthenic syndrome, congenital 5 , acute contagious conjunctivitis
KV2.1, epsin, KCR1, ICA, KV10.2, ALG10B, CaM, slop, RABEP1, CTTN
Quinidine, astemizole, E-4031, terfenadine, dofetilide, haloperidol, imipramine,
Patch Clamp: whole cell, state- and use-dependance, temperature control
Gutman et al. (2005) International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57(4):473-508